NatWest Group’s Alexion Pharmaceuticals ALXN Stock Holding History

NatWest Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-4,657	Closed	-$728K	–	366
2015 Q3	$728K	Buy	+4,657	New	+$849K	0.02%	225
2015 Q2	–	Sell	-4,725	Closed	-$819K	–	442
2015 Q1	$819K	Buy	4,725 +1,057	+29%	+$191K	0.01%	248
2014 Q4	$679K	Buy	3,668 +366	+11%	+$67.8K	0.01%	266
2014 Q3	$547K	Buy	+3,302	New	+$542K	﹤0.01%	337
2014 Q1	–	Sell	-18,099	Closed	-$2.4M	–	720
2013 Q4	$2.4M	Buy	18,099 +3,456	+24%	+$415K	0.06%	250
2013 Q3	$1.7M	Sell	14,643 -6,699	-31%	-$735K	0.05%	289
2013 Q2	$1.97M	Buy	+21,342	New	+$2.06M	0.03%	331

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NatWest Group's ALXN Position: Q4 2015 in Review

NatWest Group sold out of Alexion Pharmaceuticals (ALXN) in Q4 2015, closing a stake of 4,657 shares — an estimated $728K sold.

NatWest Group first reported a position in ALXN in Q2 2013 and held it in 7 quarters. The position peaked at $2.4M in Q4 2013. 549 funds tracked by Wall St. Rank hold ALXN as of Q4 2015.

NatWest Group reported no remaining Alexion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
NatWest Group sold 4,657 Alexion Pharmaceuticals shares in Q4 2015, an estimated $728K.
NatWest Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 7 quarters.
NatWest Group's Alexion Pharmaceuticals position peaked at $2.4M in Q4 2013.
549 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.